"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Descriptor ID |
D009369
|
| MeSH Number(s) |
C04
|
| Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 11 | 3 | 14 |
| 2005 | 4 | 2 | 6 |
| 2006 | 8 | 1 | 9 |
| 2007 | 11 | 2 | 13 |
| 2008 | 11 | 1 | 12 |
| 2009 | 10 | 3 | 13 |
| 2010 | 14 | 4 | 18 |
| 2011 | 12 | 4 | 16 |
| 2012 | 14 | 6 | 20 |
| 2013 | 15 | 6 | 21 |
| 2014 | 16 | 2 | 18 |
| 2015 | 19 | 1 | 20 |
| 2016 | 32 | 2 | 34 |
| 2017 | 24 | 1 | 25 |
| 2018 | 26 | 4 | 30 |
| 2019 | 28 | 7 | 35 |
| 2020 | 44 | 3 | 47 |
| 2021 | 50 | 2 | 52 |
| 2022 | 39 | 1 | 40 |
| 2023 | 20 | 0 | 20 |
| 2024 | 10 | 3 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Three-Dimensional In Vitro Cell Cultures as a Feasible and Promising Alternative to Two-Dimensional and Animal Models in Cancer Research. Int J Biol Sci. 2024; 20(13):5293-5311.
-
Protocol for establishing and evaluating a cancer cachexia mouse model. STAR Protoc. 2024 Sep 20; 5(3):103281.
-
PF-06952229, a selective TGF-?-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep; 9(9):103653.
-
Financial hardship screening among Native American patients with cancer: a qualitative analysis. BMC Health Serv Res. 2024 Aug 14; 24(1):928.
-
Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model. Oncologist. 2024 Jul 05; 29(7):e918-e921.
-
Proteomics Analysis of Interactions between Drug-Resistant and Drug-Sensitive Cancer Cells: Comparative Studies of Monoculture and Coculture Cell Systems. J Proteome Res. 2024 Jul 05; 23(7):2608-2618.
-
Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024 Jul 01; 42(19):2336-2357.
-
Health Care Lobbying and Oncology. J Natl Compr Canc Netw. 2024 04 19; 22(4):226-230.
-
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 Mar; 46(3):228-238.
-
Pain coping, multidisciplinary care, and mHealth: Patients' views on managing advanced cancer pain. Psychooncology. 2024 Feb; 33(2):e6308.